Serum calprotectin in vasculitis associated with antineutrophil cytoplasmic antibodies ; Сывороточный кальпротектин при васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами

Συγγραφείς: E. N. Vorkel, T. M. Reshetnyak, K. S. Nurbaeva, M. V. Cherkasova, G. M. Tarasova, O. N. Egorova, A. M. Lila, Е. Н. Воркель, Т. М. Решетняк, К. С. Нурбаева, М. В. Черкасова, Г. М. Тарасова, О. Н. Егорова, А. М. Лила

Συνεισφορές: The article has been conducted within basic scientific topic № 122040400024-7., Статья подготовлена в рамках фундаментальной научной темы № 122040400024-7.

Πηγή: Modern Rheumatology Journal; Том 18, № 4 (2024); 66-73 ; Современная ревматология; Том 18, № 4 (2024); 66-73 ; 2310-158X ; 1996-7012

Θεματικοί όροι: нейтрофилы, activity, calprotectin, inflammatory markers, neutrophils, ассоциированный с антинейтрофильными цитоплазматическими антителами, активность, кальпротектин, маркеры воспаления

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1622/1498; https://mrj.ima-press.net/mrj/article/view/1622/1511; Kitching AR, Anders HJ, Basu N, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020 Aug;6(1):71. doi:10.1038/s41572-020-0204-y.; Бекетова ТВ. Алгоритм диагностики системных васкулитов, ассоциированных с антинейтрофильными цитоплазматическими антителами. Терапевтический архив. 2018;90(5):13-21.; Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. doi:10.1002/art.37715.; Tomasson G, Grayson PC, Mahr AD, et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis – a meta-analysis. Rheumatology (Oxford). 2012 Jan;51(1):100-9. doi:10.1093/rheumatology/ker280.; Wiik A. Clinical and pathophysiological significance of anti-neutrophil cytoplasmic autoantibodies in vasculitis syndromes. Mod Rheumatol. 2009;19(6):590-9. doi:10.1007/s10165-009-0219-4.; Walulik A, Lysak K, B aszkiewicz M, et al. The Role of Neutrophils in ANCA-Associated Vasculitis: The Pathogenic Role and Diagnostic Utility of Autoantibodies. Int J Mol Sci. 2023 Dec 7;24(24):17217. doi:10.3390/ijms242417217.; Базарный ВВ. Возможности автоматизированного анализа крови в оценке нейтрофильных гранулоцитов (обзор литературы). Клиническая лабораторная диагностика. 2023;68(11):686-693.; Nacken W, Roth J, Sorg C, Kerkhoff C. S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech. 2003 Apr 15;60(6):569-80. doi:10.1002/jemt.10299.; Romand X, Bernardy C, Nguyen MVC, et al. Systemic calprotectin and chronic inflammatory rheumatic diseases. Joint Bone Spine. 2019 Nov;86(6):691-698. doi:10.1016/j.jbspin.2019.01.003.; Manfredi M, van Hoovels L, Benucci M, et al. Circulating Calprotectin (cCLP) in autoimmune diseases. Autoimmun Rev. 2023 May;22(5):103295. doi:10.1016/j.autrev.2023.103295.; Frosch M, Strey A, Vogl T, et al. Myeloidrelated proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000 Mar;43(3):628-37. doi:10.1002/1529-0131(200003)43:33.0.CO;2-X.; Viemann D, Barczyk K, Vogl T, et al. MRP8/MRP14 impairs endothelial integrity and induces a caspase-dependent and -independent cell death program. Blood. 2007 Mar 15;109(6):2453-60. doi:10.1182/blood-2006-08-040444.; Pepper RJ, Hamour S, Chavele KM, et al. Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCAassociated vasculitis and glomerulonephritis. Kidney Int. 2013 Jun;83(6):1150-8. doi:10.1038/ki.2013.2.; Anton-Pampols P, Martinez Valenzuela L, et al. Combining neutrophil and macrophage biomarkers to detect active disease in ANCA vasculitis: a combinatory model of calprotectin and urine CD163. Clin Kidney J. 2022 Dec 7;16(4):693-700. doi:10.1093/ckj/sfac257.; Romand X, Paclet MH, Chuong MV, et al. Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial. RMD Open. 2023 Oct;9(4):e003477. doi:10.1136/rmdopen-2023-003477.; Martinez Valenzuela L, Draibe J, Quero Ramos M, et al. Calprotectin as a smoldering activity detection tool and renal prognosis biomarker in ANCA associated vasculitis. PLoS One. 2018 Oct 22;13(10): e0205982. doi:10.1371/journal.pone.0205982.; Van Hoovels L, Bossuyt X. Serum calprotectin as promising diagnostic aid in predicting relapse in proteinase 3-antineutrophil cytoplasmatic antibodies-associated vasculitis. J Lab Precis Med. 2017;2:10. doi:10.21037/jlpm.2017.03.04.; Michailidou D, Duvvuri B, Kuley R, et al. Neutrophil activation in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis. Arthritis Res Ther. 2022 Jun 29;24(1):160. doi:10.1186/s13075-022-02849-z.; Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990 Aug; 33(8):1101-7. doi:10.1002/art.1780330807.; Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990 Aug;33(8): 1094-100. doi:10.1002/art.1780330806.; Robson JC, Grayson PC, Ponte C, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022 Mar;81(3):315-320. doi:10.1136/annrheumdis-2021-221795.; Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis. 2022 Mar;81(3):309-314. doi:10.1136/annrheumdis-2021-221794.; Suppiah R, Robson JC, Grayson PC, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis. 2022 Mar;81(3):321-326. doi:10.1136/annrheumdis-2021-221796.; Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009 Dec;68(12):1827-32. doi:10.1136/ard.2008.101279.; Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997 Feb;40(2): 371-80. doi:10.1002/art.1780400222.; Thieblemont N, Wright HL, Edwards SW, Witko-Sarsat V. Human neutrophils in autoimmunity. Semin Immunol. 2016 Apr;28(2): 159-73. doi:10.1016/j.smim.2016.03.004.; Pepper RJ, Draibe JB, Caplin B, et al. Association of Serum Calprotectin (S100A8/A9) Level with Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis. Arthritis Rheumatol. 2017 Jan;69(1):185-193. doi:10.1002/art.39814.; Liu C. Detection of serum interleukin-18 level and neutrophil/lymphocyte ratio in patients with antineutrophil cytoplasmic antibody-associated vasculitis and its clinical significance. Open Life Sci. 2024 Feb 5;19(1):20220823. doi:10.1515/biol-2022-0823.; Lee LE, Pyo JY, Ahn SS, et al. Systemic inflammation response index predicts allcause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Int Urol Nephrol. 2021 Aug;53(8):1631-1638. doi:10.1007/s11255-020-02777-4.; Bai X, Xu PC, Chen T, et al. The potential pathogenic roles of S100A8/A9 and S100A12 in patients with MPO-ANCA-positive vasculitis. BMC Immunol. 2022 Sep 10;23(1):42. doi:10.1186/s12865-022-00513-4.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1622
https://doi.org/10.14412/1996-7012-2024-4-66-73

Eosinophilic granulomatosis with polyangiitis: diagnosis and treatment-related issues ; Эозинофильный гранулематоз с полиангиитом: диагностические и терапевтические проблемы

Συγγραφείς: E. Kh. Anaev, N. P. Kniajeskaia, Э. Х. Анаев, Н. П. Княжеская

Πηγή: PULMONOLOGIYA; Том 33, № 4 (2023); 542-551 ; Пульмонология; Том 33, № 4 (2023); 542-551 ; 2541-9617 ; 0869-0189

Θεματικοί όροι: лечение, eosinophils, hypereosinophilia, ANCA-associated vasculitis, interleukin-5, myeloperoxidase, diagnosis, treatment, эозинофилы, гиперэозинофилия, васкулит, ассоциированный с антинейтрофильными цитоплазматическими антителами, интерлейкин-5, миелопероксидаза, диагностика

Περιγραφή αρχείου: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/4118/3547; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4118/1468; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4118/1469; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4118/1491; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4118/1492; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4118/1493; Nguyen Y., Guillevin L. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Semin. Respir. Crit. Care Med. 2018; 39 (4): 471-481. DOI:10.1055/s-0038-1669454.; Probst M., Slevogt H. Eosinophile granulomatose mit polyangiitis. Pneumologie. 2022; 76 (1): 15-16. DOI:10.1055/a-1538-9531.; Furuta S., Iwamoto T., Nakajima H. Update on eosinophilic granulomatosis with polyangiitis. Allergol. Int. 2019; 68 (4): 430-436. DOI:10.1016/j.alit.2019.06.004.; Navarro-Mendoza E.P., Tobdn G.J. Eosinophilic granulomatosis with polyangiitis: newer therapies. Curr. Rheumatol. Rep. 2018; 20 (5): 23. DOI:10.1007/s11926-018-0736-2.; Wechsler M.E., Akuthota P., Jayne D. et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N. Engl. J. Med. 2017; 376 (20): 1921-1932. DOI:10.1056/NEJMoa1702079.; Comarmond C., Pagnoux C., Khellaf M. et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013; 65 (1): 270-281. DOI:10.1002/art.37721.; Hellmich B., Csernok E., Gross W.L. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann. N. Y. Acad. Sci. 2005; 1051: 121-131. DOI:10.1196/annals.1361.053.; Marvisi C., Sinico R.A., Salvarani C. et al. New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group. Intern. Emerg. Med. 2019; 14 (8): 1193-1197. DOI:10.1007/s11739-019-02166-5.; Bayrak Durmaz M.S., Qelebi Sozener Z., Bavbek S. Eosinophilic granulomatosis with polyangitis: a new target for biologicals. Tuberk. Toraks. 2022; 70 (1): 93-101. DOI:10.5578/tt.20229911.; Khoury P., Grayson P.C., Klion A.D. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat. Rev. Rheumatol. 2014; 10 (8): 474-483. DOI:10.1038/nrrheum.2014.98.; Анаев Э.Х., Чучалин А.Г. Легочные эозинофилии: диагностика, подходы к терапии. Пульмонология. 2012; (4): 106-115. DOI:10.18093/0869-0189-2012-0-4-106-115.; Yasir M., Goyal A., Bansal P., Sonthalia S. Corticosteroid adverse effects. Treasure Island (FL): StatPearls Publishing; 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK531462/ [Accessed July 30, 2022].; Masi A.T., Hunder G.G., Lie J.T. et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990; 33 (8): 1094-1100. DOI:10.1002/art.1780330806.; Keogh K.A., Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am. J. Med. 2003; 115 (4): 284-290. DOI:10.1016/s0002-9343(03)00359-0.; Yilmaz І., Tutar N., Sim§ek Z.O. et al. Clinical and serological features of eosinophilic and vasculitic phases of eosinophilic granulomatosis with poliangiitis: a case series of 15 patients. Turk. Thorac. J. 2017; 18 (3): 72-77. DOI:10.5152/TurkThoracJ.2017.16040.; Sinico R.A., Di Toma L., Maggiore U. et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005; 52 (9): 2926-2935. DOI:10.1002/art.21250.; Nanzer A.M., Wechsler M.E. Eosinophilic granulomatosis with polyangiitis. In: Jackson D.J., Wechsler M.E., eds. Eosinophilic lung diseases. [ERS monograph]. Sheffield: European Respiratory Society; 2022: 177-192. DOI:10.1183/2312508X.10029820.; Cottin V., Khouatra C., Dubost R. et al. Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome and long-term follow-up. Allergy. 2009; 64 (4): 589-595. DOI:10.1111/j.1398-9995.2008.01854.x.; Kataoka H., Tomita T., Kondo M., Masaya Mukai M. Presence of purpura is related to active inflammation in association with IL-5 in eosinophilic granulomatosis with polyangiitis. Rheumatol. Int. 2021; 41 (2): 449-454. DOI:10.1007/s00296-020-04672-8.; Geetha D., Jefferson J.A. ANCA-associated vasculitis: core curriculum 2020. Am. J. Kidney Dis. 2020; 75 (1): 124-137. DOI:10.1053/j.ajkd.2019.04.031.; Sinico R.A., Bottero P. Churg-Strauss angiitis. Best Pract. Res. Clin. Rheumatol. 2009; 23 (3): 355-366. DOI:10.1016/j.berh.2009.02.004.; Wechsler M.E. Pulmonary eosinophilic syndromes. Immunol. Allergy Clin. North Am. 2007; 27 (3): 477-492. DOI:10.1016/j.iac.2007.07.005.; Gioffredi A., Maritati F., Oliva E., Buzio C. Eosinophilic granulomatosis with polyangiitis: an overview. Front. Immunol. 2014; 5: 549. DOI:10.3389/fimmu.2014.00549.; Vaglio A., Strehl J.D., Manger B. et al. IgG4 immune response in Churg-Strauss syndrome. Ann. Rheum. Dis. 2012; 71 (3): 390-393. DOI:10.1136/ard.2011.155382.; Dejaco C., Oppl B., Monach P. et al. Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). PLoS One. 2015; 10 (3): e0121737. DOI:10.1371/journal.pone.0121737.; Dallos T., Heiland G.R., Strehl J. et al. CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum. 2010; 62 (11): 3496-3503. DOI:10.1002/art.27678.; Vaglio A., Zwerina J. IgG4-related disease. N. Engl. J. Med. 2012; 366 (17): 1643-1647. DOI:10.1056/NEJMc1202768.; Vaglio A., Casazza I., Grasselli C. et al. Churg-Strauss syndrome. Kidney Int. 2009; 76 (9): 1006-1011. DOI:10.1038/ki.2009.210.; Schleimer R.P., Bochner B.S. The effects of glucocorticoids on human eosinophils. J. Allergy Clin. Immunol. 1994; 94 (6, Pt 2): 12021213. DOI:10.1016/0091-6749(94)90333-6.; Новиков П.И., Зыкова А.С., Моисеев С.В. Современная терапия системных васкулитов: достижения и перспективы. Терапевтический архив. 2018; 90 (1): 76-85. DOI:10.17116/terarkh201890176-85.; Kahn J.E., Grandpeix-Guyodo C., Marroun I. et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J. Allergy Clin. Immunol. 2010; 125 (1): 267-270. DOI:10.1016/j.jaci.2009.10.014.; Yates M., Watts R.A., Bajema I.M. et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann. Rheum. Dis. 2016; 75 (9): 1583-1594. DOI:10.1136/annrheum-dis-2016-209133.; Ribi C., Cohen P., Pagnoux C. et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized open-label study of seventy-two patients. Arthritis Rheum. 2008; 58 (2): 586-594. DOI:10.1002/art.23198.; Guillevin L., Pagnoux C., Seror R. et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculit-ides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011; 90 (1): 19-27. DOI:10.1097/MD.0b013e-318205a4c6; Cohen P., Pagnoux C., Mahr A. et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007; 57 (4): 686-693. DOI:10.1002/art.22679.; Saku A., Furuta S., Hiraguri M. et al. Long-term outcomes of 188 Japanese patients with eosinophilic granulomatosis with polyangiitis. J. Rheumatol. 2018; 45 (8): 1159-1166. DOI:10.3899/jrheum.171352.; Tsurikisawa N., Taniguchi M., Saito H. et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann. Allergy Asthma Immunol. 2004; 92 (1): 80-87. DOI:10.1016/S1081-1206(10)61714-0.; Puechal X., Pagnoux C., Baron G. et al. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis or polyarteritis nodosa without poor prognosis factors: a random-ized-controlled trial. Arthritis Rheumatol. 2017; 69 (11): 2175-2186. DOI:10.1002/art.40205.; Tsukadaira A., Okubo Y., Kitano K. et al. Eosinophil active cytokines and surface analysis of eosinophils in Churg-Strauss syndrome. Allergy Asthma Proc. 1999; 20 (1): 39-44. DOI:10.2500/108854199778681486.; Fagni F., Bello F., Emmi G. Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology. Front. Med. (Lausanne). 2021; 8: 627776. DOI:10.3389/fmed.2021.627776.; Rosenberg H.F., Phipps S., Foster P.S. Eosinophil trafficking in allergy and asthma. J. Allergy Clin. Immunol. 2007; 119 (6): 1303-1310. DOI:10.1016/j.jaci.2007.03.048.; Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9842): 651-659. DOI:10.1016/S0140-6736(12)60988-X.; Rothenberg M.E., Klion A.D., Roufosse F.E. et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N. Engl. J. Med 2008; 358 (12): 1215-1228. DOI:10.1056/NEJ-Moa070812.; Stein M.L., Collins M.H., Villanueva J.M. et al. Anti-IL-5 (mepoli-zumab) therapy for eosinophilic esophagitis. J. Allergy Clin. Immunol. 2006; 118 (6): 1312-1319. DOI:10.1016/j.jaci.2006.09.007.; Steinfeld J., Bradford E.S., Brown J. et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J. Allergy Clin. Immunol. 2019; 143 (6): 2170-2177. DOI:10.1016/j.jaci.2018.11.041.; Jachiet M., Samson M., Cottin V. et al. Anti-IgE monoclonal antibody (Omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients. Arthritis Rheumatol. 2016; 68 (9): 2274-2282. DOI:10.1002/art.39663.; Wechsler M.E., Hickey L., Garin M. et al. Efficacy of reslizumab treatment in exacerbation-prone patients with severe eosinophilic asthma. J. Allergy Clin. Immunol. Pract. 2020; 8 (10): 3434-3442. DOI:10.1016/j.jaip.2020.06.009.; Kent B.D., d'Ancona G., Fernandes M. et al. Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. ERJ Open Res. 2020; 6 (1): 003112019. DOI:10.1183/23120541.00311-2019.; Nanzer A.M., Dhariwal J., Kavanagh J. et al. Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis. ERJ Open Res. 2020; 6 (4): 00451-2020. DOI:10.1183/23120541.00451-2020.; Guntur V.P., Manka L.A., Denson J.L. et al. Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. J. Allergy Clin. Immunol. Pract. 2021; 9 (3): 1186-1193. e1. DOI:10.1016/j.jaip.2020.09.054.; Manka L.A., Guntur V.P., Denson J.L. et al. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Ann. Allergy Asthma Immunol. 2021; 126 (6): 696-701.e1. DOI:10.1016/j.anai.2021.01.035.; Mohammad A.J., Hot A., Arndt F. et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann. Rheum. Dis. 2016; 75 (2): 396-401. DOI:10.1136/annrheum-dis-2014-206095.; Roccatello D., Baldovino S., Alpa M. et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin. Exp. Rheumatol. 2008; 26 (3, Suppl. 49): S67-71. Available at: https://pubmed.ncbi.nlm.nih.gov/18799057/; Seeliger B., Forster M., Happe J. et al. Interferon-a for induction and maintenance of remission in eosinophilic granulomatosis with polyangiitis: a single-center retrospective observational cohort study. J. Rheumatol. 2017; 44 (6): 806-814. DOI:10.3899/jrheum.160907.; Lyons P., Peters J., Alberici F. et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat. Commun. 2019; 10 (1): 5120. DOI:10.1038/s41467-019-12515-9.; Mukhtyar C., Flossmann O., Hellmich B. et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European league against rheumatism systemic vasculitis task force. Ann. Rheum. Dis. 2008; 67 (7): 1004-1010. DOI:10.1136/ard.2007.071936.; Mahr A., Moosig F., Neumann T. et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etio-pathogenesis, assessment and management. Curr. Opin. Rheumatol. 2014; 26 (1): 16-23. DOI:10.1097/BOR.0000000000000015.; Gayraud M., Guillevin L., le Toumelin P. et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. 2001; 44 (3): 666-675. DOI:10.1002/1529-0131(200103)44:33.0.CO;2-A.; Exley A.R., Bacon P.A., Luqmani R.A. et al. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br. J. Rheumatol. 1998; 37 (1): 57-63. DOI:10.1093/rheumatology/37.1.57.; Arbach O., Metzler C., Gause A. [Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients]. Z. Rheumatol. 2004; 63 (4): 339-340. DOI:10.1007/s00393-004-0538-y (in German).; https://journal.pulmonology.ru/pulm/article/view/4118

Διαθεσιμότητα: https://journal.pulmonology.ru/pulm/article/view/4118
https://doi.org/10.18093/0869-0189-2022-4118

РОССИЙСКИЙ ОПЫТ ПРИМЕНЕНИЯ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К В-ЛИМФОЦИТАМ (РИТУКСИМАБ) ПРИ СИСТЕМНЫХ ВАСКУЛИТАХ, АССОЦИИРОВАННЫХ С АНТИНЕЙТРОФИЛЬНЫМИ ЦИТОПЛАЗМАТИЧЕСКИМИ АНТИТЕЛАМИ (ПРЕДВАРИТЕЛЬНЫЕ РЕЗУЛЬТАТЫ РОССИЙСКОГО РЕГИСТРА НОРМА)

Συγγραφείς: Бекетова, Татьяна, Александрова, Е., Новоселова, Т., Сажина, Е., Николаева, Е., Сороцкая, В., Земерова, Е., Нам, И., Никитина, Н., Архангельская, Г., Багаутдинова, З., Дашков, И., Черных, С., Жирова, О., Лушпаева, Ю., Маснева, Л., Афанасьева, И., Арсеньев, А., Кондратенко, И., Башкова, И., Глухова, С., Насонов, Е., Смирнов, А.

Θεματικοί όροι: СИСТЕМНЫЙ ВАСКУЛИТ, АССОЦИИРОВАННЫЙ С АНТИНЕЙТРОФИЛЬНЫМИ ЦИТОПЛАЗМАТИЧЕСКИМИ АНТИТЕЛАМИ, ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ ВЕГЕНЕРА, МИКРОСКОПИЧЕСКИЙ ПОЛИАНГИИТ, ЭОЗИНОФИЛЬНЫЙ ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ ЧЕРДЖА-СТРОС, БИОЛОГИЧЕСКАЯ АНТИ-В-КЛЕТОЧНАЯ ТЕРАПИЯ, РИТУКСИМАБ, WEGENER''S GRANULOMATOSIS WITH POLYANGIITIS, EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS SYNDROM)

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/rossiyskiy-opyt-primeneniya-monoklonalnyh-antitel-k-v-limfotsitam-rituksimab-pri-sistemnyh-vaskulitah-assotsiirovannyh-s
http://cyberleninka.ru/article_covers/15616969.png

Российский опыт применения моноклональных антител к В-лимфоцитам (ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра норма)

Πηγή: Научно-практическая ревматология.

Θεματικοί όροι: СИСТЕМНЫЙ ВАСКУЛИТ, АССОЦИИРОВАННЫЙ С АНТИНЕЙТРОФИЛЬНЫМИ ЦИТОПЛАЗМАТИЧЕСКИМИ АНТИТЕЛАМИ, ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ ВЕГЕНЕРА, МИКРОСКОПИЧЕСКИЙ ПОЛИАНГИИТ, ЭОЗИНОФИЛЬНЫЙ ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ ЧЕРДЖА-СТРОС, БИОЛОГИЧЕСКАЯ АНТИ-В-КЛЕТОЧНАЯ ТЕРАПИЯ, РИТУКСИМАБ, WEGENER'S GRANULOMATOSIS WITH POLYANGIITIS, EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS SYNDROM), 3. Good health

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article/n/rossiyskiy-opyt-primeneniya-monoklonalnyh-antitel-k-v-limfotsitam-rituksimab-pri-sistemnyh-vaskulitah-assotsiirovannyh-s
http://cyberleninka.ru/article_covers/15616969.png